4:59 PM · 11 October 2022

Amgen surges after Morgan Stanley upgrade

Amgen (AMGN.US) stock surged more than 6.0% after Morgan Stanley upgraded the biopharma company to overweight from equal weight, saying Amgen is “largely de risked” and provides defensiveness for investors.

Analysts believe the market is not appreciating upside potential that stems from the potential of obesity candidate AMG133, which could differentiate itself against others in the competitive obesity market through better weight loss, improved dosing frequency, and better tolerability.

Amgen (AMGN.US) stock rose sharply on Tuesday and managed to break above local resistance at $244.50, which coincides with 23.6% Fibonacci retracement of the last upward wave. Nevertheless, upward move was halted at the upper limit of the triangle formation and as long as price sits below, another downward impulse may be launched. Source: xStation5

4 November 2026, 3:11 PM

US OPEN: Blue Wave in Congress Triggers Massive Wall Street Rally, Dow Gains Over 1,000 Points

4 November 2026, 1:25 PM

Market Wrap: European Stocks Rise Following US Elections

4 November 2026, 12:27 PM

Spain Is Back on Its Feet 🚀 Trump's Nemesis Makes a Comeback After the Midterm Elections 📈

4 November 2026, 11:14 AM

Novo Nordisk Earnings: Downtrend is slowing down

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits